The latest announcement is out from PDS Biotechnology ( (PDSB) ).
PDS Biotechnology Corporation announced compelling results from the IMMUNOCERV Phase 2 clinical trial for Versamune® HPV with chemoradiation in treating advanced cervical cancer at the ASTRO Annual Meeting 2024. The trial showcased a remarkable 36-month overall survival rate of 84.4%, with a 100% rate in patients fully treated with the drug, significantly outperforming historical data. Achieving a complete metabolic response in 88% of patients, Versamune® HPV also demonstrated a safe and well-tolerated profile, positioning the company for further investigation into this promising treatment.
See more insights into PDSB stock on TipRanks’ Stock Analysis page.
